UK drug firm Shire recommends takeover by US rival AbbVie

Automatic Inspection Machine - Ampules Shire is known primarily as a maker of drugs to treat rare diseases

Related Stories

British drug firm Shire is recommending a takeover offer from US rival AbbVie after its most recent offer of £53.20 ($91.05) per share.

The board of the UK pharmaceutical company says it will be recommending the offer to shareholders.

The US company began bidding for Shire in May. The deal is an attractive one for AbbVie, as it could dramatically reduce its tax bill.

AbbVie had raised its offer to £51.15 ($87.54) per share last Tuesday.

Under the new offer, Shire shareholders would own approximately 25% of the combined new firm.

Shire, which is based in Basingstoke, Hampshire, said in a statement: "The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders, subject to satisfactory resolution of the other terms of the offer."

Shire's shares rose 5.9% to close at £48.70 in London on Friday, valuing the company at £28.7bn. AbbVie's closed at $54.95 (down 0.76%).

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Business stories

RSS

Features

  • Alpine ibexGoing, going, goat

    Why you're less likely to see an Alpine ibex than your parents were


  • Kouayou KouayouDon't copy me

    The man with 26 children who's preaching birth control


  • Female Kurdish peshmerga fightersWhose war?

    Jeremy Bowen asks who will fight IS on the ground


  • Inside the Shakespeare Theatre in GdanskPoland-on-Avon

    Opening night for Shakespeare theatre... in Gdansk


From BBC Capital

Programmes

  • A person taking a photo of fireworks on a smartphoneClick Watch

    A look at the latest gadgets which could make it easier to take the perfect night-time picture

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.